BioCryst Deferred Long Term Liab from 2010 to 2024
| BCRX Stock | USD 7.53 0.07 0.92% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 81 K | Current Value 54 K | Quarterly Volatility 4 M |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 113.7 M or Selling General Administrative of 209.1 M, as well as many indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Deferred Long Term Liab |
Latest BioCryst Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of BioCryst Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. BioCryst Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
BioCryst Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 2,910,718 | |
| Geometric Mean | 430,739 | |
| Coefficient Of Variation | 128.54 | |
| Mean Deviation | 3,399,959 | |
| Median | 155,000 | |
| Standard Deviation | 3,741,553 | |
| Sample Variance | 14T | |
| Range | 9.6M | |
| R-Value | (0.72) | |
| Mean Square Error | 7.3T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (599,161) | |
| Total Sum of Squares | 196T |
BioCryst Deferred Long Term Liab History
About BioCryst Pharmaceuticals Financial Statements
BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 48.6 K | 46.2 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.